Related Experiment Video
Updated: Jan 20, 2026

In Ovo Xenografting of Patient-Derived Acute Lymphoblastic Leukemia (ALL) Cells (PDX-ALL)
Published on: August 1, 2025
Treatment response and outcome of children with T-cell acute lymphoblastic leukemia expressing the gamma-delta T-cell
Ching-Hon Pui1,2,3, Deqing Pei4, Cheng Cheng4
1Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN, USA.
Insights
Pediatric T-cell acute lymphoblastic leukemia (T-ALL) expressing the gamma delta T-cell receptor (γδ TCR) shows a poorer response to treatment and decreased survival rates compared to other T-ALL patients, despite risk-directed therapy.
Area of Science:
- Oncology
- Immunology
- Pediatric Hematology
Background:
- Gamma delta T-cell receptor (γδ TCR) expressing T-cell malignancies are linked to poor prognoses.
- Understanding the clinical outcomes of pediatric T-cell acute lymphoblastic leukemia (T-ALL) with γδ TCR expression is crucial for treatment stratification.
Purpose of the Study:
- To determine the clinical outcome of pediatric patients with T-cell acute lymphoblastic leukemia (T-ALL) expressing the γδ T-cell receptor (TCR).
Main Methods:
- Analysis of γδ TCR repertoire in 93 newly diagnosed pediatric T-ALL patients using paired sequencing.
- Evaluation of minimal residual disease (MRD) at specific time points during remission induction.
- Comparison of clinical outcomes, including survival rates, between γδ T-ALL and other T-ALL patient groups.
Main Results:
- 13% of pediatric T-ALL patients expressed γδ TCR.
- γδ T-ALL patients showed significantly higher rates of MRD ≥ 1% on day 15-19 (67% vs. 33%) and day 42-49 (33% vs. 7%) compared to other T-ALL patients.
- The 10-year overall survival for γδ T-ALL patients (66.7%) was significantly lower than for other T-ALL patients (93.3%).
Conclusions:
- Pediatric γδ T-ALL is associated with a poor response to remission induction therapy, indicated by higher MRD levels.
- Children with γδ T-ALL exhibit decreased survival rates compared to other T-ALL patients, even with risk-directed therapy.
- The findings suggest a need for tailored therapeutic strategies for pediatric γδ T-ALL.
Abstract:
T-cell malignancies expressing the γδ T-cell receptor (TCR) are often associated with poor prognosis. Here, we determined the clinical outcome of pediatric patients with T-cell acute lymphoblastic leukemia (T-ALL) expressing the γδ TCR. Of 100 newly diagnosed T-ALL patients, 93 had γδ TCR analysis performed at diagnosis. Repertoire was evaluated by paired sequencing of the rearranged TCR. All patients received intensified chemotherapy and those with minimal residual disease (MRD) ≥ 1% on day 42-46 became candidates for hematopoietic cell transplantation. Of the 93 T-ALL patients, 12 (13%) had γδ T-ALL and 11 (12%) had early T-cell precursor (ETP) ALL. Compared to the remaining 70 T-ALL patients, the γδ T-ALL patients were more likely to have MRD ≥ 1% on day 15-19 (67% vs. 33%, P = 0.03) and day 42-49 (33% vs. 7%; P = 0.007) of remission induction. The 10-year overall survival for γδ T-ALL patients (66.7% ± 22.2%) were lower than that of T-ALL patients (93.3% ± 7.3%, P = 0.001). TCR analysis demonstrated a conserved clonotype. In conclusion, the data suggest that children with γδ T-ALL may have a poor response to remission induction, based on MRD levels and decreased survival than the other T-ALL patients, despite receiving risk-directed therapy.
Related Concept Videos
The Delta-to-Delta Circuit
Cell Specific Gene Expression
Cell Specific Gene Expression
Types of Receptors: Cell Surface Receptors
Internal Receptors
The Y-to-Delta Circuit
The initial step in analyzing a wye-to-delta circuit is to assume a positive phase sequence. These phase voltages are then utilized to calculate the line voltages that occur directly across the delta-connected load impedances. Van, Vbn, and Vcn are the phase voltages in wye, and Vab, Vbc, and Vca are the line voltages for a delta circuit. The relation between...

